Natixis Advisors, L.P. Abb Vie Inc. Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Abb Vie Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 1,197,850 shares of ABBV stock, worth $231 Million. This represents 0.4% of its overall portfolio holdings.
Number of Shares
1,197,850
Previous 1,213,411
1.28%
Holding current value
$231 Million
Previous $240 Million
11.17%
% of portfolio
0.4%
Previous 0.47%
Shares
30 transactions
Others Institutions Holding ABBV
# of Institutions
4,064Shares Held
1.28BCall Options Held
17.8MPut Options Held
15.7M-
Vanguard Group Inc Valley Forge, PA173MShares$33.4 Billion0.55% of portfolio
-
Black Rock Inc. New York, NY136MShares$26.3 Billion0.54% of portfolio
-
State Street Corp Boston, MA79.6MShares$15.4 Billion0.57% of portfolio
-
Jpmorgan Chase & CO New York, NY51.8MShares$9.98 Billion0.75% of portfolio
-
Morgan Stanley New York, NY39.7MShares$7.65 Billion0.51% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $341B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...